Unnecessary Expense

An Antidote for the Billion Dollar Drug Problem

Charles Theuer, Bonne Adams, Mark Wiggins, Scott Brown (Autoren)

Buch | Hardcover

192 Seiten

2021
Forbes Books (Verlag)
978-1-950863-57-0 (ISBN)

Lieferbar (Termin unbekannt)
Versandkostenfrei
Auch auf Rechnung

Artikel merken

The drug development process in the United States has become so weighted down by a business-as-usual paradigm that an average of more than $2 billion is spent to secure FDA approval for every new drug. Because the investment required is so extreme, drug development companies are understandably focused on discovering and developing drugs designed for large patient populations: diseases experienced by millions, such as high blood pressure, diabetes, or some of the more common cancers.
In Unnecessary Expense, Dr. Charles Theuer, CEO of TRACON Pharmaceuticals, outlines the problem and offers a solution: an aligned and streamlined model that emphasizes quality and reduces the time and cost of drug development, while also harnessing global innovation to benefit patients with rare diseases in urgent need of new treatments. Here Dr. Theuer shows the value of a pharmaceutical paradigm shift, to enable the development of drugs for patients who need them, at a fraction of the time and cost.

DR. CHARLES THEUER has been CEO and President and a Director of TRACON Pharmaceuticals since 2006. Dr. Theuer has been instrumental in bringing novel blockbuster oncology drugs to market, including Sutent® to treat advanced kidney cancer, while working as Director of Clinical Oncology at Pfizer. Dr. Theuer has held senior management positions at notable biotechnology firms, including TargeGen, Inc., and IDEC Pharmaceutical Corp. He has worked at the National Cancer Institute and held academic positions at the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology. He is married with two adult children and enjoys hiking, coaching basketball, and sculling.

FOREWORD INTRODUCTION THE BILLION-DOLLAR DRUG PROBLEM JOURNEY FROM ONCOLOGY SURGEON TO BIOTECHNOLOGY EXECUTIVE BIOTECHNOLOGY LESSONS BIG PHARMA LESSONS CROS—THE PITFALLS OF BUSINESS AS USUAL IN DRUG DEVELOPMENT UNDERSTANDING AND NAVIGATING THE FDA THE TRACON PRODUCT DEVELOPMENT PLATFORM HARNESSING GLOBAL INNOVATION FOR US PATIENTS INTEGRATING TECHNOLOGY AS PART OF THE TRACON PDP THE FINER POINTS OF COMMERCIALIZING AN ONCOLOGY DRUG SUMMARY ACKNOWLEDGMENTS GLOSSARY ABOUT THE LEAD AUTHOR OUR SERVICES

Erscheinungsdatum	31.08.2021
Sprache	englisch
Maße	152 x 231 mm
Themenwelt	Medizin / Pharmazie ► Pharmazie
	Technik
	Wirtschaft ► Betriebswirtschaft / Management ► Unternehmensführung / Management
ISBN-10	1-950863-57-3 / 1950863573
ISBN-13	978-1-950863-57-0 / 9781950863570
Zustand	Neuware